Read More

Marker Therapeutics Highlights Will Present Data From Investigator-Sponsored Phase 1 Study With Its MultiTAA-Specific T Cells To Be Presented At American Society Of Hematology Dec. 12, 2021 At 12:30 p.m. EST

Researchers from Baylor College of Medicine to review results from STELLA study in oral presentation HOUSTON, Nov. 18, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage

MRKR